Combination topical therapy for conjunctival primary acquired melanosis with atypia and periocular lentigo maligna

Cornea. 2015 Jan;34(1):90-3. doi: 10.1097/ICO.0000000000000277.

Abstract

Purpose: To report the case of a patient who initially presented with primary acquired melanosis (PAM) without atypia of the conjunctiva and later developed lentigo maligna of the eyelids and PAM with atypia of the conjunctiva. We illustrate the utility of combination topical therapy with adjunctive cryotherapy to treat extensive eyelid and conjunctival lesions.

Methods: Case report with a review of the current literature.

Results: Combination of imiquimod 5% cream (Aldara, 3M Pharmaceuticals) and cryotherapy for periorbital lentigo maligna with topical interferon-α2b for conjunctival PAM with atypia led to clinical resolution of pigmented lesions for 21 months.

Conclusions: In our experience, combination topical therapy provides an effective alternative to surgery with superior cosmetic and functional outcomes.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Aged, 80 and over
  • Aminoquinolines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Conjunctival Diseases / pathology
  • Conjunctival Diseases / therapy*
  • Cryotherapy / methods*
  • Eyelid Neoplasms / pathology
  • Eyelid Neoplasms / therapy*
  • Female
  • Humans
  • Hutchinson's Melanotic Freckle / pathology
  • Hutchinson's Melanotic Freckle / therapy*
  • Imiquimod
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Melanosis / pathology
  • Melanosis / therapy*
  • Recombinant Proteins / administration & dosage

Substances

  • Aminoquinolines
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Imiquimod